STOCK TITAN
  1. Home
  2. Sec-filings
  3. COCP
  4. [8-K] Cocrystal Pharma, Inc. Reports Material Event

Cocrystal Pharma (COCP) reports death of board director Japour

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Cocrystal Pharma, Inc. reported that board member Dr. Anthony Japour passed away on March 10, 2026. The company filed this current report to formally disclose his death as a change in its board of directors. The filing is signed by Co-Chief Executive Officer and Chief Financial Officer James Martin.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Understanding 8-K Material Events →
false 0001412486 0001412486 2026-03-10 2026-03-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 10, 2026

 

Cocrystal Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38418   35-2528215

(State or other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

19805 N. Creek Parkway

Bothell, WA

   98011
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (877) 262-7123

 

 

(Former name or former address, if changed since last report.):

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   COCP  

The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Cocrystal Pharma, Inc. (the “Company”) sadly learned on March 10, 2026 that Dr. Anthony Japour, a member of the Company’s board of directors, passed away.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  COCRYSTAL PHARMA INC.
   
Date: March 13, 2026 /s/ James Martin
  James Martin
  Co-Chief Executive Officer and Chief Financial Officer

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What did Cocrystal Pharma (COCP) disclose in this 8-K filing?

Cocrystal Pharma disclosed that board member Dr. Anthony Japour passed away on March 10, 2026. The report formally records this change in the company’s board composition and is signed by Co-Chief Executive Officer and Chief Financial Officer James Martin.

Who from Cocrystal Pharma (COCP) signed the March 2026 8-K?

The 8-K is signed by James Martin, who serves as Co-Chief Executive Officer and Chief Financial Officer of Cocrystal Pharma. His signature indicates the company has authorized and approved the disclosure regarding the death of director Dr. Anthony Japour.

Which Cocrystal Pharma (COCP) director passed away in March 2026?

Director Dr. Anthony Japour passed away, as Cocrystal Pharma learned on March 10, 2026. The company reported his death in this current report as a change affecting its board of directors under the item covering departures of directors and related matters.

What is the main purpose of this Cocrystal Pharma (COCP) 8-K?

The main purpose is to notify investors and the market that board member Dr. Anthony Japour has died. This event is reported under the item addressing departures of directors, ensuring transparency about changes in the company’s governance structure.

On what date did Cocrystal Pharma (COCP) learn of Dr. Japour’s passing?

Cocrystal Pharma learned on March 10, 2026 that director Dr. Anthony Japour had passed away. That date is specifically referenced in the report and serves as the event date triggering this current disclosure about the board change.

Filing Exhibits & Attachments

3 documents

Other Documents